The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Featured:
During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, AU, about the efficacy of the novel T-cell bispecific engaging antibody, CD20-TCB (RG6026), for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL).
Michael Dickinson describes CD20-TCB as a CD20 CD3 bispecific antibody, which was tested in non-Hodgkin lymphoma, targeting CD20. Despite toxicities being observed in patients, it is still early days, with promising results for patients with a very aggressive refractory condition.
ICML 2019 | Efficacy of novel T-cell bispecific engaging antibody, CD20-TCB (RG6026), for R/R NHL